Astragaloside II-loaded neutrophil nanocarrier drug delivery system for liver cancer treatment
Journal of Biomaterials Applications · 2026
DOI: 10.1177/08853282251381435 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biomaterials Applications, 2026. Verfasst von Guangyi Gao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Huai'an Second People's Hospital, Affiliated to Xuzhou Medical University, Huai'an, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Saponins, Neutrophils, Triterpenes. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Huai’an Science and Technology Program.
Abstract (Originalsprache)
Background
Liver cancer is one of the most lethal cancers globally, with current treatments offering limited efficacy and significant side effects. Astragaloside II (ASII), a compound derived from traditional Chinese medicine, shows promise in reducing adverse effects, improving patient constitution, and prolonging survival. However, its clinical application is hindered by poor solubility and distribution. This study aims to develop a neutrophil-based nanocarrier system to enhance the tumor-targeting capability and therapeutic efficacy of ASII.
Methods
We encapsulated ASII within PEG-PLGA nanomicelles and loaded them into neutrophils to create a neutrophil nanocarrier system (PG@AS-Neu). The physical properties of PG@AS-Neu were characterized using dynamic light scattering (DLS) and transmission electron microscopy. The encapsulation efficiency and release profile of ASII were investigated using high-performance liquid chromatography. The inhibitory effects of ASII and PG@AS-Neu on liver cancer cells were evaluated through cell viability, apoptosis, scratch wound, Transwell, and hemolysis assays to assess the nanocarrier’s biosafety.
Results
The neutrophil nanocarrier system demonstrated excellent stability and intact cellular morphology. Hemolysis assays confirmed the nanocarrier’s blood compatibility. Cell viability, apoptosis, and invasion and migration assays revealed that both ASII and PG@AS-Neu significantly inhibited liver cancer cells. The preparation process of PG@AS-Neu did not compromise the anticancer activity of ASII, showing similar efficacy to free ASII.
Conclusion
PG@AS-Neu exhibits potent anticancer effects and holds significant potential for liver cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Huai'an Second People's Hospital, Affiliated to Xuzhou Medical University, Huai'an, China.
- Department of Oncology, Huai'an TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Huai'an, China.
- Department of Ultrasound, Huai'an Second People's Hospital, Affiliated to Xuzhou Medical University, Huai'an, China.
ORCID-Profile: Zeai Wang
Förderung
- Huai’an Science and Technology Program
Zitieren
APA
Gao, G., Jiang, X., Ma, J., & Wang, Z. (2026). Astragaloside II-loaded neutrophil nanocarrier drug delivery system for liver cancer treatment. Journal of Biomaterials Applications. https://doi.org/10.1177/08853282251381435
Vancouver
Gao G, Jiang X, Ma J, Wang Z. Astragaloside II-loaded neutrophil nanocarrier drug delivery system for liver cancer treatment. Journal of Biomaterials Applications. 2026. doi:10.1177/08853282251381435
BibTeX
@article{Gao2026,
author = {Gao, Guangyi and Jiang, Xuan and Ma, Jun and Wang, Zeai},
title = {Astragaloside II-loaded neutrophil nanocarrier drug delivery system for liver cancer treatment},
journal = {Journal of Biomaterials Applications},
year = {2026},
doi = {10.1177/08853282251381435}
}
EUVIMED